Abstract
Background The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), designated as a variant of concern by the World Health Organization, spreads globally and was confirmed as the cause of the Omicron wave of the coronavirus disease 2019 (COVID-19) pandemic in Shanghai, China. The viral shedding duration of Omicron variants needs to be determined.
Methods We retrospectively analyzed 382 patients admitted to a shelter hospital for COVID-19. Of the patients, 8 patients were referred to a designated hospital, 100 were infected asymptomatic patients, and 274 patients had mild COVID-19.
Results The vaccination rates (including fully and boosted) in the asymptomatic and mild COVID-19 patients were 92.00% and 94.16%, respectively. Majority of the studied population showed a first reverse transcription-polymerase chain reaction cycle threshold (Ct) value of 20. For 2565 nasopharyngeal swabs from close or sub-close contacts, the Ct value gradually increased to 35 for 8 days, and the median duration of viral shedding time was 10 days after the first positive detection of the SARS-CoV-2 nuclei acid.
Conclusions Quantitative viral RNA load assays in COVID-19 (BA.2.2.1) close or sub-closed contacts could be used to prevent transmissions and control precautions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by Zhejiang Provincial Natural Science Foundation of China (grant number Y23H190011), the Key Program of Natural Science Foundation of Ningbo (grant number 202003N4019), and Ningbo City COVID-19 Epidemic Prevention and Control Project (grant number 202002N7033).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective study was conducted at the Cixi Dapengshan Shelter Hospital (managed by Ningbo First Hospital, University of Ningbo), and this study was approved by the Ethics Committee of Ningbo First Hospital (approval No. 2022RS065). Written informed consent from patients was waived because this was a retrospective study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- COVID-19
- Coronavirus disease 2019
- RT-PCR
- Reverse Transcription-Polymerase Chain Reaction
- Ct
- Cycle threshold
- CDC
- Center for Disease Control and Prevention
- CT
- Computed Tomography
- VOC
- Variants of Concern
